All Stories

  1. DRESS Syndrome and Daclizumab Failure—Were Potentially Dangerous Signs Missed in Clinical Trials?

    Article • Drug Target Insights, January 2018, SAGE Publications

    Dr Jagannadha R Avasarala

  2. Multiple Sclerosis brain in 3D

    Article • F1000Research, August 2017, Faculty of 1000, Ltd.

    Dr Jagannadha R Avasarala

  3. Fingolimod use pitfalls

    Article • The Journal of Clinical Pharmacology, May 2017, Wiley

    Dr Jagannadha R Avasarala, Dr Enrique Urrea-Mendoza

  4. Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

    Article • Drug Target Insights, January 2017, SAGE Publications

    Dr Jagannadha R Avasarala

  5. Is A Neurologist Needed to Diagnose Acute Stroke in the Emergency Department?

    Article • JAMA Neurology, September 2016, American Medical Association (AMA)

    Dr Jagannadha R Avasarala

  6. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosisAuthor Response

    Article • Neurology, July 2016, Wolters Kluwer Health

    Dr Jagannadha R Avasarala

  7. Overdiagnosis of idiopathic intracranial hypertensionAuthor Response

    Article • Neurology, June 2016, Wolters Kluwer Health

    Dr Jagannadha R Avasarala

  8. The TOUCH program and natalizumab: Fundamental flaw in patient protection

    Article • F1000Research, May 2016, Faculty of 1000, Ltd.

    Dr Jagannadha R Avasarala

  9. Applying the Principles of McDonaldization to Medicine

    Article • JAMA Neurology, April 2016, American Medical Association (AMA)

    Dr Jagannadha R Avasarala

  10. The TOUCH program and natalizumab: Fundamental flaw in patient protection

    Article • F1000Research, February 2016, Faculty of 1000, Ltd.

    Dr Jagannadha R Avasarala

  11. Computer-aided Therapeutics in Treating Autoimmune Encephalitis

    Article • JAMA Neurology, January 2016, American Medical Association (AMA)

    Dr Jagannadha R Avasarala

  12. TOUCH PROGRAM IS FLAWED

    Article • F1000Research, December 2015, Faculty of 1000, Ltd.

    Dr Jagannadha R Avasarala

  13. Diagnosing Lymphomatosis Cerebri

    Article • JAMA Neurology, December 2015, American Medical Association (AMA)

    Dr Jagannadha R Avasarala

  14. Vitamin D deficiency in multiple sclerosis: Should testing and treatment be based on racial background?

    Article • Journal of the Neurological Sciences, November 2015, Elsevier

    Dr Jagannadha R Avasarala

  15. Letter by Avasarala Regarding Article, “2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Hear...

    Article • Stroke, October 2015, Wolters Kluwer Health

    Dr Jagannadha R Avasarala

  16. Newer multiple sclerosis drugs and disability scores-are key data analyses missing?

    Article • The Journal of Clinical Pharmacology, June 2015, Wiley

    Dr Jagannadha R Avasarala

  17. Clinically isolated syndrome — Rethinking the diagnosis

    Article • Journal of the Neurological Sciences, June 2015, Elsevier

    Dr Jagannadha R Avasarala

  18. Multiple sclerosis in US minority populations: Clinical practice insights

    Article • Neurology Clinical Practice, June 2015, Wolters Kluwer Health

    Dr Jagannadha R Avasarala

  19. Time to Rethink CIS Criteria

    Article • Multiple Sclerosis Discovery Forum, January 2015, Multiple Sclerosis Discovery Forum

    Dr Jagannadha R Avasarala

  20. Stem cell therapies in multiple sclerosis – united we stand, divided we fail

    Article • Clinical Case Reports and Reviews, January 2015, Open Access Text Pvt, Ltd.

    Dr Jagannadha R Avasarala

  21. Racial differences in clinical trials for multiple sclerosis

    Article • JAMA Neurology, August 2014, American Medical Association (AMA)

    Dr Jagannadha R Avasarala

  22. The repertoire of proteins in CSF continues to evolve.

    Article • European Journal of Neurology, September 2008, Wiley

    Dr Jagannadha R Avasarala

  23. Microarray analysis in B cells among siblings with/without MS - role for transcription factor TCF2

    Article • BMC Medical Genomics, January 2008, Springer Science + Business Media

    Dr Jagannadha R Avasarala

  24. Analysis of NAMCS data for multiple sclerosis, 1998–2004

    Article • BMC Medicine, April 2007, Springer Science + Business Media

    Dr Jagannadha R Avasarala

  25. Ventricular Obstruction From Neurocysticercosis

    Article • Archives of Neurology, June 2005, American Medical Association (AMA)

    Dr Jagannadha R Avasarala

  26. A Distinctive Molecular Signature of Multiple Sclerosis Derived from MALDI-TOF/MS and Serum Proteomic Pattern Analysis: Detection of Three Biomarkers

    Article • Journal of Molecular Neuroscience, January 2005, Springer Science + Business Media

    Dr Jagannadha R Avasarala

  27. Recombinant Erythropoietin Down-Regulates IL-6 and CXCR4 Genes in TNF-α-Treated Primary Cultures of Human Microvascular Endothelial Cells: Implications for Multiple Sclerosis

    Article • Journal of Molecular Neuroscience, January 2005, Springer Science + Business Media

    Dr Jagannadha R Avasarala

  28. Neurological Disorders: Course and Treatment

    Article • Archives of Neurology, June 2004, American Medical Association (AMA)

    Dr Jagannadha R Avasarala

  29. Comparative assessment of Yale Single Q uestion and Beck Depression Inventory Scale in screening for depression in multiple sclerosis

    Article • Multiple Sclerosis Journal, June 2003, SAGE Publications

    Dr Jagannadha R Avasarala

  30. Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

    Article • Multiple Sclerosis Journal, February 2003, SAGE Publications

    Dr Jagannadha R Avasarala

  31. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department

    Article • Journal of Emergency Medicine, April 2002, Elsevier

    Dr Jagannadha R Avasarala

  32. Oligoclonal Band Number as a Marker for Prognosis in Multiple Sclerosis

    Article • Archives of Neurology, December 2001, American Medical Association (AMA)

    Dr Jagannadha R Avasarala

  33. Surrogate Markers in Multiple Sclerosis

    Article • Archives of Neurology, May 2001, American Medical Association (AMA)

    Dr Jagannadha R Avasarala

  34. Inflammatory trigeminal sensory neuropathy

    Article • Neurology, July 1997, Wolters Kluwer Health

    Dr Jagannadha R Avasarala

  35. Prognostic Factors in Squamous Cell Carcinoma of the Larynx

    Article • Auris Nasus Larynx, January 1992, Elsevier

    Dr Jagannadha R Avasarala

  36. Distribution of peptidases in cultured cells from middle ear mucosa: Prolyl endopeptidase is localized in fibroblasts and dipeptidyl peptidase IV and II in epithelial cells

    Article • Biochemical Medicine and Metabolic Biology, June 1991, Elsevier

    Dr Jagannadha R Avasarala

  37. Presence of dipeptidyl peptidase II, dipeptidyl peptidase IV, and prolyl endopeptidase in effusion from patients with serous otitis media

    Article • Biochemical Medicine and Metabolic Biology, June 1990, Elsevier

    Dr Jagannadha R Avasarala

  38. Spectral Analysis of Airflow Sounds in Patent Versus Occluded Tracheostomy Tubes

    Article • The Laryngoscope, May 1990, Wiley

    Dr Jagannadha R Avasarala

  39. Laryngeal Pacemaker

    Article • The Laryngoscope, July 1988, Wiley

    Dr Jagannadha R Avasarala

  40. Use of Pulse Oximetry for Monitoring Tracheostomy Tube Obstruction

    Article • ORL, January 1988, Karger Publishers

    Dr Jagannadha R Avasarala